. 2020 Dec 30;33(1):mzaa166. doi: 10.1093/intqhc/mzaa166

Table 3.

PET-CT indications for lung, CRC and oesophagogastric cancers across ICBP jurisdictions

		Lung						CRC						Oesophagogastric^a
Jurisdiction	S	RS	AS	Su	TP	TA	RE	S	RS	Su	TP	TA	RE	S	RS	M	TP	TA	RE
Alberta	•	•	•	•	•	•	•		•	•	•		•	•	•	•	•		•
Australia	•		•		•	•	•		•		•		•	•			•	•	•
Denmark	•				•				•		•	•	•	•
England	•		•		•	•	•		•		•	•	•	•			•	•	•
Ireland	•		•		•		•		•		•	•	•	•			•	•	•
New Zealand	•		•		•				•		•	•	•	•			•
Norway	•		•		•		•							•	•		•	•	•
Nova Scotia	•		•	•									•	•	•	•
Northern Ireland	•		•			•			•		•	•	•	•
Ontario	•	•	•		•		•		•		•		•	•	•			•	•
Saskatchewan	•		•		•				•						•		•	•
Scotland	•		•		•		•				•		•	•			•		•
Wales	•		•		•		•		•					•			•

S = Staging; RS = Restaging; AS = Assessment of solitary pulmonary nodule; Su = Surveillance; TP = Treatment planning^b; TA = Treatment assessment; RE = Recurrence evaluation.

^{^a}

primarily focused on oesophageal and GOJ tumours; evidence is more varied and emerging for gastric cancers.

^{^b}

Treatment planning refers to aiding guidance upon treatment decision e.g. chemotherapy or surgery.